Guidelines
Acute Cystitis and Pyelonephritis

Acute Cystitis and Pyelonephritis

Notes

References

1) Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20. 2) Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2006;40:643-54. 3) FDA updates warnings for fluoroquinolone antibiotics. U.S. Food & Drug Administration. Released 26 July 2016. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm 4) Dan S, Shah A, Justo JA, et al. Prediction of fluoroquinolone resistance in gram-negative bacteria causing bloodstream infections. Antimicrob Agents Chemother 2016; 60:2265-72. 5) Shah A, Justo JA, Bookstaver PB, et al. Application of fluoroquinolone resistance score in management of complicated urinary tract infections. Antimicrob Agents Chemother 2017; 61: e02313-16. 6) Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50. 7) Veve MP, Wagner JL, Kenny RM, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infection. Int J Antimicrob Agents 2016;48:56-60. 8) Hayes JE, O’Quinn B, Lu K, et al. Fosfomycin resistance among vancomycin-resistant enterococcal isolates at a tertiary care medical center. Presented at American College of Clinical Pharmacy 2016; Abstract # 176. 9) Hammer KL, Justo J, Bookstaver PB, et al. Differential effect of prior β-lactams and fluoroquinolones on risk of bloodstream infections secondary to Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2017 Jan;87(1):87-91. 10) Augustine M, Testerman TL, Justo J, et al. Clinical risk score for prediction of extended-spectrum beta-lactamase-producing Enterobacteriaceae in bloodstream isolates. Infect Control Hosp Epidemiol 2017; 38: 266-272. 11) Pichichero ME. Cephalosporins can be prescribed safely for penicillin-allergic patients. J Fam Pract 2006;55:106-12 12) Jeffres MN, Narayanan PP, Shuster JE, Schramm GE. Consequences of avoiding β-lactams in patients with β-lactam allergies. J Allergy Clin Immunol 2016;137:1148-53. 13) Hoang P, Salbu RL. Updated nitrofurantoin recommendations in the elderly: a closer look at the evidence. Consult Pharm 2016 Jul;31:381-4. 14) Nelson AN, Justo JA, Bookstaver PB, et al. Optimal duration of antimicrobial therapy for uncomplicated gram-negative bloodstream infections. Infection 2017; 45: 613-20. 15) Kutob LF, Justo JA, Bookstaver PB, et al. Effectiveness of oral antibiotics for definitive therapy of gram-negative bloodstream infections. Int J Antimicrob Agents 2016; 48: 498-503.

1) Gupta K, Hooten TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20. 2) Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2006;40:643-54. 3) FDA updates warnings for fluoroquinolone antibiotics. U.S. Food & Drug Administration. Released 26 July 2016. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm 4) Pichichero ME. Cephalosporins can be prescribed safely for penicillin-allergic patients. J Fam Pract 2006;55:106-12. 5) Shah A, Justo JA, Bookstaver PB, et al. Application of fluoroquinolone resistance score in management of complicated urinary tract infections. Antimicrob Agents Chemother 2017; 61: e02313-16. 6) Falagas ME, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50. 7) Veve MP, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infection. Int J Antimicrob Agents 2016;48:56-60. 8) Sanasi-Bhola K, et al. Fosfomycin in vitro activity against extended spectrum beta-lactamase positive and carbapenem resistant Enterobacteriaceae urine isolates. Presented at IDWeek 2014. Abstract #40851. 9) Hayes JE, O’Quinn B, Lu K, et al. Fosfomycin resistance among vancomycin-resistant enterococcal isolates at a tertiary care medical center. Presented at American College of Clinical Pharmacy; 2016; Abstract #176. 10) Hoang P, Salbu RL. Updated nitrofurantoin recommendations in the elderly: a closer look at the evidence. Consult Pharm 2016 Jul;31:381-4.